CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • February 16th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This License Agreement (“Agreement”), made as of 16 February 2024 (“Effective Date”), is by and among Fusion Pharmaceuticals Inc having an address at 270 Longwood Road South Hamilton, Ontario, Canada L8P 0A6 (“Fusion”) and Universität Heidelberg having an address at Grabengasse 1, 69117, Heidelberg, Germany (“UH”) and Euratom represented by the European Commission, Joint Research Centre (“EURATOM”), having an address at B-1049, Brussels, Belgium (“Euratom”). EURATOM, Fusion, and UH are each referred to individually as a “Party” and together as the “Parties.” UH and EURATOM, co-owner of the Licensed patents, are together referred to as “Licensors” or “Licensor” as applicable.
